Shopping Cart
  • Remove All
  • TargetMol
    Your shopping cart is currently empty

IRAK

The interleukin-1 receptor (IL-1R) associated kinase (IRAK) family plays a crucial role in the protective response to pathogens introduced into the human body by inducing acute inflammation followed by additional adaptive immune responses. IRAKs are essential components of the Interleukin-1 receptor signaling pathway and some Toll-like receptor signaling pathways. Toll-like receptors (TLRs) detect microorganisms by recognizing specific pathogen-associated molecular patterns (PAMPs) and IL-1R family members respond the interleukin-1 (IL-1) family cytokines. These receptors initiate an intracellular signaling cascade through adaptor proteins, primarily, MyD88. This is followed by the activation of IRAKs. TLRs and IL-1R members have a highly conserved amino acid sequence in their cytoplasmic domain called the Toll/Interleukin-1 (TIR) domain. The elicitation of different TLRs/IL-1Rs results in similar signaling cascades due to their homologous TIR motif leading to the activation of mitogen-activated protein kinases (MAPKs) and the IκB kinase (IKK) complex, which initiates a nuclear factor-κB (NF-κB) and AP-1-dependent transcriptional response of pro-inflammatory genes. Understanding the key players and their roles in the TLR/IL-1R pathway is important because the presence of mutations causing the abnormal regulation of Toll/IL-1R signaling leading to a variety of acute inflammatory and autoimmune diseases.IRAKs are membrane proximal putative serine-threonine kinases. Four IRAK family members have been described in humans: IRAK1, IRAK2, IRAKM, and IRAK4. Two are active kinases, IRAK-1 and IRAK-4, and two are inactive, IRAK-2 and IRAK-M, but all regulate the nuclear factor-κB (NF-κB) and mitogen-activated protein kinase (MAPK) pathways.

Ginsenoside Rb1
T282241753-43-9
Ginsenoside Rb1 (Gypenoside Ⅲ) is part of a class of steroid glycosides; may have properties that inhibit or prevent the growth of tumors.
  • $39
In Stock
Size
QTY
Zabedosertib
T370761931994-81-8In house
Zabedosertib (BAY 1834845) is an inhibitor of IRAK4 with immunomodulatory potential. Zabedosertib protects against acute respiratory distress syndrome, a new study suggests.
  • $36
In Stock
Size
QTY
IRAK4-IN-10
T619312681278-09-9In house
IRAK4-IN-10 (compound 75) is a potent IRAK4 inhibitor (IC50 = 1.5 nM) that can block the MyD88-dependent signaling pathway and has research potential in inflammatory diseases, autoimmune diseases, and cancer.
  • $633
In Stock
Size
QTY
IRAK4-IN-8
T633882033070-97-0In house
IRAK4-IN-8 (VI-177) is an IRAK4 inhibitor used to study diseases related to cancer and inflammation.
  • $868 TargetMol
In Stock
Size
QTY
AS-2444697
T42991287665-60-4
AS-2444697 is an inhibitor of IRAK-4 (C50 = 21 nM). AS-2444697 exhibits renoprotective effects through anti-inflammatory action. AS-2444697 potently inhibits human and rat IRAK-4 activity.
  • $30
In Stock
Size
QTY
Edecesertib
T624732408839-73-4
Edecesertib (GS-5718) is a selective, orally active IRAK-4 inhibitor with anti-inflammatory properties, applicable for the study of rheumatoid arthritis (RA) and lupus erythematosus (LE).
  • $699
In Stock
Size
QTY
IRAK4-IN-20
T627141931994-80-7
IRAK4-IN-20 is a potent and orally active IRAK4 inhibitor (IC50:3.55 nM). IRAK4-IN-20, which has anti-inflammatory, antitumor and anticancer effects, is often used to treat acute respiratory distress syndrome (ARDS).
  • $195
In Stock
Size
QTY
TargetMol | Inhibitor Sale
IRAK-1-4 Inhibitor I
T2457509093-47-4
IRAK-1-4 Inhibitor I is a dual inhibitor targeting IRAK1 and IRAK4.
  • $37
In Stock
Size
QTY
TargetMol | Inhibitor Sale
Zimlovisertib
TQ01671817626-54-2
Zimlovisertib (PF-06650833) is an effective, selective and orally active inhibitor of interleukin-1 receptor-associated kinase 4 (IRAK4) (IC50s: 0.2 and 2.4 nM in the cell and PBMC assay).
  • $39
In Stock
Size
QTY
Larotinib
T733341438072-11-7
Larotinib is an orally active, potent, and broad-spectrum tyrosine kinase inhibitor (TKI) with an IC50 of 0.6 nM for EGFR.
  • $74
In Stock
Size
QTY
AZ1495
T143672196204-23-4
AZ1495 is an oral active inhibitor of Interleukin-1 receptor associated kinase 4 (IRAK4), with IC50 values of 5 nM and 23 nM for IRAK4 and IRAK1, respectively. Which Shows activity in treatment of mutant MYD88L265P diffuse large B-cell lymphoma (DLBCL).
  • $148
In Stock
Size
QTY
TargetMol | Inhibitor Sale
IRAK4-IN-1
T41401820787-94-7
IRAK4-IN-1 is an interleukin-1 receptor-associated kinase 4 (IRAK4) inhibitor with an IC50 of 7 nM.
  • $64
In Stock
Size
QTY
TargetMol | Inhibitor Sale
CA-4948
T90271801344-14-8
CA-4948 (Emavusertib) is a potent IRAK4 FLT3 inhibtor. CA-4948 with anti-tumor activity.
  • $30
In Stock
Size
QTY
IRAK inhibitor 1
T50941042224-63-4
IRAK inhibitor 1 is an effective IRAK-4 inhibitor (IC50: 216 nM), is poorly active against JNK-1 (IC50: 3.801 μM) and JNK-2 (IC50>10 μM).
  • $87
In Stock
Size
QTY
TargetMol | Inhibitor Sale
JH-X-119-01
T92032227368-54-7
JH-X-119-01 is a highly potent and selective covalent inhibitor of IRAK-1 (Interleukin-1 Receptor-Associated Kinase 1).
  • $60
In Stock
Size
QTY
TargetMol | Inhibitor Sale
HS-243
T60012848249-10-5
HS-243 is an inhibitor of IRAK-4 and IRAK-1 with IC50s of 20 and 24 nM. HS-243 shows anti-inflammatory and anticancer activity.
  • $48
In Stock
Size
QTY
IRAK4-IN-7
T53541801343-74-7
IRAK4-IN-7 (CA-4948) is a selective and potent IRAK4 kinase inhibitor with in vivo activity in a TLR4-induced cytokine release model.
  • $31
In Stock
Size
QTY
IRAK inhibitor 6
T51101042672-97-8
IRAK inhibitor 6 is an inhibitor of interleukin-1 receptor-associated kinase 4 [IRAK-4, IC50: 160 nM].
  • $48
In Stock
Size
QTY
GLPG2534
T751132095615-97-5In house
GLPG2534 is an orally active, selective and potent IRAK4 inhibitor with anti-inflammatory activity. GLPG2534 inhibits human and mouse IRAK4 and could be used to study psoriasis and atopic dermatitis.
  • $113
In Stock
Size
QTY
HS271
T370822410393-15-4In house
HS271 is a selective, highly potent and orally active IRAK4 inhibitor (IC50= 7.2 μM). HS271 shows excellent enzymatic and cellular activities, as well as excellent pharmacokinetic properties.
  • $56
In Stock
Size
QTY
TargetMol | Inhibitor Sale
Thalidomide 4-fluoride
T7755835616-60-9
Thalidomide 4-fluoride (E3 ligase Ligand 4) (Cereblon ligand 4) is the Thalidomide-based Cereblon ligand. Thalidomide 4-fluoride can be used in the recruitment of CRBN protein. Thalidomide 4-fluoride (Cereblon ligand 4) can be connected to the ligand for IRAK4 protein by a linker to form PROTAC IRAK4 degrader-1.
  • $29
In Stock
Size
QTY
TargetMol | Inhibitor Sale
IRAK inhibitor 2
T7368928333-30-6In house
IRAK inhibitor 2 (IRAK-IN-2) is a potent inhibitor of interleukin 1 receptor-associated kinase 4 (IRAK-4) for the study of inflammation-related diseases.
  • $78
In Stock
Size
QTY
IRAK4-IN-4
T116731850276-58-2
IRAK4-IN-4 (compound 15) inhibits cyclic GMP-AMP synthase (cGAS) with an IC50 of 2.1 nM.IRAK4-IN-4 is an interleukin-1 receptor–associated kinase 4 (IRAK4) inhibitor, has an IC50 of 2.8 nM.
  • $58
In Stock
Size
QTY
TargetMol | Inhibitor Sale
IRAK-4 protein kinase inhibitor 2
T9631301675-24-1
IRAK-4 protein kinase inhibitor 2 is a potent inhibitor of interleukin-1 receptor-associated kinase-4 (IC50 = 4 μM).
  • $37
In Stock
Size
QTY
TargetMol | Inhibitor Sale
IRAK inhibitor 3
T116701012343-93-9
IRAK inhibitor 3 is a modulator of interleukin-1 (IL-1) receptor-associated kinase (IRAK).
  • $143
In Stock
Size
QTY
IRAK4-IN-24
T78744
IRAK4-IN-24 (compound 16), a potent IRAK4 inhibitor, exhibits high clearance (Cl) and low oral bioavailability. It is utilized in research pertaining to inflammatory and autoimmune disorders.
  • Inquiry Price
Size
QTY
IRAK4-IN-25
T79447
IRAK4-IN-25 (compound 38), a potent oral IRAK4 inhibitor (IC50 = 7.3 nM) with low clearance (Cl = 12 mL/min/kg), effectively suppresses pro-inflammatory cytokine production and demonstrates favorable in vitro safety and ADME profiles. It is suitable for research on inflammatory and autoimmune disorders [1].
  • Inquiry Price
Size
QTY
BI1543673
T200483
BI1543673 is an inhibitor of interleukin-1 receptor-associated kinase 4 (IRAK4). It can diminish inflammatory responses in human lung tissue stimulated by TLR4 and TLR7 8. Additionally, BI1543673 reduces inflammatory signaling in a mouse lung inflammation model induced by LPS.
  • Inquiry Price
Size
QTY
IRAK4-IN-27
T79485
IRAK4-IN-27 (Compound 22) is a potent and selective IRAK4 inhibitor with an IC50 of 8.7 nM. It effectively suppresses cell growth and induces apoptosis in the MYD88 L265P diffuse large B-cell lymphoma (DLBCL) cell line, making it a valuable agent for DLBCL research [1].
  • Inquiry Price
Size
QTY
IRAK4-IN-28
T793372952532-92-0
IRAK4-IN-28 (compound 42), an orally-active IRAK4 inhibitor (IC50=8.9 nM), exhibits strong binding affinity with a Kd of 0.58 nM for the target enzyme. It is utilized for research purposes in the study of inflammation and autoimmune diseases [1].
  • $1,970
8-10 weeks
Size
QTY
IRAK4-IN-26
T79448
IRAK4-IN-26 (Compound 21), an IRAK4 inhibitor with an IC50 of 6.2 nM, exhibits an oral bioavailability of 21%. It is utilized for the study of inflammatory and autoimmune disorders [1].
  • Inquiry Price
Size
QTY
PROTAC IRAK4 degrader-8
T790972911615-06-8
PROTAC IRAK4 Degrader-8 (Compound 2) is a PROTAC designed to target IRAK4 with an IC50 of 15.5 nM [1].
  • Inquiry Price
8-10 weeks
Size
QTY